GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Intrinsic Value: Projected FCF

Sight Sciences (Sight Sciences) Intrinsic Value: Projected FCF : $0.00 (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-22), Sight Sciences's Intrinsic Value: Projected FCF is $0.00. The stock price of Sight Sciences is $5.46. Therefore, Sight Sciences's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Sight Sciences's Intrinsic Value: Projected FCF or its related term are showing as below:

SGHT's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.75
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Sight Sciences Intrinsic Value: Projected FCF Historical Data

The historical data trend for Sight Sciences's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Intrinsic Value: Projected FCF Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Sight Sciences Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sight Sciences's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Sight Sciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Price-to-Projected-FCF falls into.



Sight Sciences Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Sight Sciences  (NAS:SGHT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Sight Sciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=5.46/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sight Sciences Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Sight Sciences's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sight Sciences (Sight Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Executives
Jeremy B. Hayden officer: Chief Legal Officer 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park officer: Chief Operating Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi director, 10 percent owner, officer: President and CEO C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi director, officer: Chief Technology Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p. 10 percent owner 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz director C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link officer: Chief Commercial Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein officer: See remarks 326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg officer: See Remarks C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker director C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick officer: Chief Financial Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim 10 percent owner C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089

Sight Sciences (Sight Sciences) Headlines

From GuruFocus

Sight Sciences Announces Addition of New Director Catherine Mazzacco

By sperokesalga sperokesalga 06-09-2023